<DOC>
	<DOC>NCT01159691</DOC>
	<brief_summary>The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions after changing treatment to Neupro® transdermal patch in patients suffering from idiopathic Parkinson´s Disease with gastrointestinal symptoms while being treated with oral antiparkinson drugs. The objective of the study is to ascertain whether switching therapy to Neupro® transdermal patch can provide any relief in gastrointestinal symptoms.</brief_summary>
	<brief_title>Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch</brief_title>
	<detailed_description>Routine treatment as per approved label in Europe in accordance with the terms of the local marketing authorization for Neupro®.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>The decision to prescribe Neupro® must have been made by the physician before and independently of his/her decision to include the patient in the study The patient's treatment must be in accordance with the terms of the local marketing authorization (MA) for Neupro® The patient must have a diagnosis of Idiopathic Parkinson's disease The patient must have signed the Consent form regarding study information, data transfer and use Patient suffering from gastrointestinal symptoms while being treated with oral Parkinson's medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Parkinson's disease</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Switch from oral therapy to patch</keyword>
</DOC>